Syqe Medical is an Israeli pharma-tech company developing technologies for the administration of raw plants and pharmaceuticals by inhalation. The company has developed the world’s first programmable pulmonary drug delivery platform, the Syqe Inhaler™, capable of administering metered doses of plants at therapeutic standards. First brought to market for use with cannabinoids, Syqe is exploring numerous molecules for a variety of therapeutic areas and is seeking strategic partnerships with leading drug manufacturers and academic centers dedicated to jointly solving the challenges of inadequate therapeutic delivery and dosing.
“Syqe Medical is excited to be named by Fast Company in their annual top ten list of the world’s most innovative biotechnology companies,” said Perry Davidson, Syqe CEO and Founder. “The technology behind the Syqe Inhaler™ has been proven in several clinical trials demonstrating that the device delivers medication in a safe fashion with breakthrough precision and with consistent and repeatable accuracy. The Syqe device allows patients to receive the clinical benefits of medical cannabis treatment while minimizing the psychoactive side effects. For the first time, healthcare practitioners can prescribe medical cannabis safely, with a defined dosage plan and a predictable outcome – as they would any other pharmaceutical product. What’s most important for us is that Syqe’s technology is changing patients’ lives today,” Davidson added.
Syqe’s patented technology introduces unprecedented precision dose control as well as inhalation automation that ensures bioavailability with normal inhalation, and remote clinical monitoring. These controls allow for the consistent release and absorption of therapeutic compounds in an aerosol form, generated in milliseconds, addressing significant shortcomings of current inhalers. The inhaler can deliver individually tailored daily treatment plans based on a patient’s clinical needs, while ensuring a consistent uniform pharmacokinetic profile. The Syqe Inhaler™ is used with preloaded cartridges of medical cannabis produced under pharmaceutical standards.
In addition to providing maximum symptom relief in minutes while minimizing side effects, the Syqe Inhaler™ drastically reduces the average monthly amount of cannabis required when compared to smoking and vaporizing. Clinical and post-market data shows patients are achieving significant symptom relief while using up to 90 percent less medical cannabis and reducing other medications, such as opioids.
“Using Syqe’s breakthrough drug delivery platform, we believe we can vastly improve patient adherence and treatment outcomes across a range of therapeutic areas,” said Davidson. “Ultimately, we aim to relieve the suffering of as many patients as possible, in the fastest possible way.”
The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year. It provides both a snapshot and a road map for the future of innovation across the most dynamic sectors of the economy.
“At a time of increasing global volatility, this year’s list showcases the resilience and optimism of businesses across the world. These companies are applying creativity to solve challenges within their industries and far beyond,” said Fast Company senior editor Amy Farley, who oversaw the issue with deputy editor David Lidsky.